{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:57:27Z","timestamp":1792796247272,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.autrev.2019.102366","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T11:44:24Z","timestamp":1565351064000},"page":"102366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":152,"title":["Next-generation Fc receptor\u2013targeting biologics for autoimmune diseases"],"prefix":"10.1016","volume":"18","author":[{"given":"Adrian W.","family":"Zuercher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Spirig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Baz Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"K\u00e4sermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.autrev.2019.102366_bb0005","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.iac.2008.06.004","article-title":"History of immunoglobulin replacement","volume":"28","author":"Eibl","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"10.1016\/j.autrev.2019.102366_bb0010","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/ncpneuro0429","article-title":"Shortage of human intravenous immunoglobulin\u2014reasons and possible solutions","volume":"3","author":"Bayry","year":"2007","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2019.102366_bb0015","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/rheumatology\/keu429","article-title":"Indications for IVIG in rheumatic diseases","volume":"54","author":"Mulhearn","year":"2015","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.autrev.2019.102366_bb0025","doi-asserted-by":"crossref","first-page":"R192","DOI":"10.1186\/ar4024","article-title":"Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice","volume":"14","author":"Jain","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.autrev.2019.102366_bb0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/jns5.12022","article-title":"Beneficial effect of a multimerized immunoglobulin Fc in an animal model of inflammatory neuropathy (experimental autoimmune neuritis)","volume":"18","author":"Niknami","year":"2013","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.autrev.2019.102366_bb0035","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaut.2013.12.014","article-title":"Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis","volume":"52","author":"Thiruppathi","year":"2014","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.autrev.2019.102366_bb0040","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121905","article-title":"A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity","volume":"4","author":"Zhang","year":"2019","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.autrev.2019.102366_bb0045","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/bloodadvances.2016001917","article-title":"A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b","volume":"1","author":"Zhou","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.autrev.2019.102366_bb0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaut.2017.08.004","article-title":"Recombinant human IgG1 based fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated disease","volume":"84","author":"Sun","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2019.102366_bb0060","author":"Gliknik"},{"issue":"365","key":"10.1016\/j.autrev.2019.102366_bb0065","doi-asserted-by":"crossref","first-page":"365ra158","DOI":"10.1126\/scitranslmed.aaf9418","article-title":"Elucidating the interplay between IgG-Fc valency and FcgammaR activation for the design of immune complex inhibitors","volume":"8","author":"Ortiz","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2019.102366_bb0080","unstructured":"Hsu Y, Lee J, Chang H, Inventors Recombinant intravenous immunoglobulin (rIVIG) compositions and methods for their production and use patent WO2017172853A1. 2017."},{"issue":"5","key":"10.1016\/j.autrev.2019.102366_bb0085","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.4049\/jimmunol.154.5.2226","article-title":"Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4","volume":"154","author":"Smith","year":"1995","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2019.102366_bb0090","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.4049\/jimmunol.156.8.2858","article-title":"Effect of the IgM and IgA secretory tailpieces on polymerization and secretion of IgM and IgG","volume":"156","author":"Sorensen","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2019.102366_bb0095","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/srep00124","article-title":"Polymeric human Fc-fusion proteins with modified effector functions","volume":"1","author":"Mekhaiel","year":"2011","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2019.102366_bb0100","doi-asserted-by":"crossref","first-page":"9526","DOI":"10.1038\/srep09526","article-title":"Developing the IVIG biomimetic, hexa-Fc, for drug and vaccine applications","volume":"5","author":"Czajkowsky","year":"2015","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.autrev.2019.102366_bb0105","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.4049\/jimmunol.1701171","article-title":"rIgG1 Fc hexamer inhibits antibody-mediated autoimmune disease via effects on complement and FcgammaRs","volume":"200","author":"Spirig","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2019.102366_bb0110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.neuropharm.2018.02.002","article-title":"Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica","volume":"133","author":"Tradtrantip","year":"2018","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.autrev.2019.102366_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17255-8","article-title":"Multivalent Fcgamma-receptor engagement by a hexameric Fc-fusion protein triggers Fcgamma-receptor internalisation and modulation of Fcgamma-receptor functions","volume":"7","author":"Qureshi","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2019.102366_bb0120","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s42003-018-0149-9","article-title":"Engineered hexavalent Fc proteins with enhanced Fc-gamma receptor avidity provide insights into immune-complex interactions","volume":"1","author":"Rowley","year":"2018","journal-title":"Commun Biol"},{"issue":"22","key":"10.1016\/j.autrev.2019.102366_bb0125","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1182\/blood.V128.22.4919.4919","article-title":"Argx-113, a novel Fc-based approach for antibody-induced pathologies such as primary immune thrombocytopenia","volume":"128","author":"Ulrichts","year":"2016","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.autrev.2019.102366_bb0130","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.autrev.2019.102366_bb0135","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.4049\/jimmunol.1003780","article-title":"Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model","volume":"187","author":"Patel","year":"2011","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2019.102366_bb0140","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4161\/mabs.25439","article-title":"Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis","volume":"5","author":"Challa","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.autrev.2019.102366_bb0145","author":"Efgartigimod"},{"issue":"23","key":"10.1016\/j.autrev.2019.102366_bb0165","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V126.23.3472.3472","article-title":"M281: a therapeutic anti-FcRn blocking antibody for rapid clearance of IgG and IgG autoantibodies in immune cytopenias and other auto\/allo-immune disease","volume":"126","author":"Ling","year":"2015","journal-title":"Blood."},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2019.102366_bb0170","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2015-eular.5290","article-title":"THU0057 targeting the neonatal FC receptor (FCRN) to mediate autoantibody clearance in IgG-driven autoimmune disease","volume":"74","author":"Ling","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.102366_bb0175","article-title":"M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study","author":"Ling","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.autrev.2019.102366_bb0185","author":"Momenta Pharmaceuticals"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2019.102366_bb0195","first-page":"3483","article-title":"SYNT001: a humanized IgG4 monoclonal antibody that disrupts the interaction of FcRn and IgG for the treatment of IgG-mediated autoimmune diseases","volume":"130","author":"Blumberg","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2019.102366_bb0200","author":"Cukier-Meisner"},{"issue":"414","key":"10.1016\/j.autrev.2019.102366_bb0220","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.autrev.2019.102366_bb0225","first-page":"1111","article-title":"Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration","volume":"10","author":"Smith","year":"2018","journal-title":"MAbs"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2019.102366_bb0245","first-page":"15","article-title":"Phase II, multiple-dose study of anti-FcRn antibody, rozanolixizumab (UCB7665), in patients with primary immune thrombocytopenia: interim analysis","volume":"130","author":"Robak","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.autrev.2019.102366_bb0255","author":"Biopharmaceutical Research Center"},{"issue":"8","key":"10.1016\/j.autrev.2019.102366_bb0265","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nbt0897-772","article-title":"Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain","volume":"15","author":"Nord","year":"1997","journal-title":"Nat Biotechnol"},{"issue":"48","key":"10.1016\/j.autrev.2019.102366_bb0270","doi-asserted-by":"crossref","first-page":"17110","DOI":"10.1073\/pnas.1417717111","article-title":"An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein","volume":"111","author":"Seijsing","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.autrev.2019.102366_bb0275","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1038\/s41598-018-23481-5","article-title":"In vivo depletion of serum IgG by an affibody molecule binding the neonatal fc receptor","volume":"8","author":"Seijsing","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.autrev.2019.102366_bb0290","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.autrev.2016.02.006","article-title":"Targeting FcgammaRs to treat antibody-dependent autoimmunity","volume":"15","author":"Yu","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2019.102366_bb0295","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s13238-017-0433-3","article-title":"Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy","volume":"9","author":"Mimura","year":"2018","journal-title":"Protein Cell"},{"issue":"31","key":"10.1016\/j.autrev.2019.102366_bb0300","doi-asserted-by":"crossref","first-page":"12994","DOI":"10.1074\/jbc.M117.795047","article-title":"Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors","volume":"292","author":"Blundell","year":"2017","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.autrev.2019.102366_bb0310","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clim.2008.02.002","article-title":"Amelioration of collagen-induced arthritis by human recombinant soluble FcgammaRIIb","volume":"127","author":"Magnusson","year":"2008","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2019.102366_bb0315","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/jid.2014.451","article-title":"Recombinant soluble CD32 suppresses disease progression in experimental epidermolysis bullosa acquisita","volume":"135","author":"Iwata","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"21","key":"10.1016\/j.autrev.2019.102366_bb0320","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood.V120.21.3388.3388","article-title":"Interim results from a phase Ib\/IIa clinical trial with the soluble fc-gamma IIb receptor SM101 for the treatment of primary immune thrombocytopenia","volume":"120","author":"Konstaninova","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.autrev.2019.102366_bb0325","article-title":"Sm101, a novel recombinant, soluble, human Fc\u03b3iib receptor, in the treatment of systemic lupus erythematosus: results of a double-blind, placebo-controlled multicenter study","volume":"66","author":"Tillmanns","year":"2014","journal-title":"Arthritis & Rheumatology"},{"issue":"1","key":"10.1016\/j.autrev.2019.102366_bb0330","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/toxsci\/kfr278","article-title":"Nonclinical evaluation of GMA161\u2014an antihuman CD16 (FcgammaRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice","volume":"125","author":"Flaherty","year":"2012","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.autrev.2019.102366_bb0340","author":"Xencor \u2013 XmAb5871"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2019.102366_bb0350","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/annrheumdis-2015-eular.2851","article-title":"FRI0161 a phase 1B\/2A study of the safety, tolerability, pharmacokinetics and pharmacodynamics of XMAB\u00ae5871 in patients with rheumatoid arthritis","volume":"74","author":"Jaraczewska-Baumann","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2019.102366_bb0365","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1586\/1744666X.2015.1049599","article-title":"Antibody replacement therapy in primary antibody deficiencies and iatrogenic hypogammaglobulinemia","volume":"11","author":"Hoffman","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2019.102366_bb0370","doi-asserted-by":"crossref","first-page":"181","DOI":"10.14785\/lpsn-2014-0025","article-title":"The history and evolution of immunoglobulin products and their clinical indications","volume":"2","author":"Hooper","year":"2015","journal-title":"LymphoSign Journal"},{"issue":"11","key":"10.1016\/j.autrev.2019.102366_bb0375","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/nbt1342","article-title":"Complement-targeted therapeutics","volume":"25","author":"Ricklin","year":"2007","journal-title":"Nat Biotechnol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219301661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219301661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:16:39Z","timestamp":1761599799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997219301661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1568997219301661"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2019.102366","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation Fc receptor\u2013targeting biologics for autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2019.102366","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102366"}}